Literature DB >> 3967809

Protection against hepatitis B virus infection by immunization with hepatitis B core antigen.

S Iwarson, E Tabor, H C Thomas, P Snoy, R J Gerety.   

Abstract

Although antibody to the hepatitis B surface antigen usually provides protection against hepatitis B virus (HBV) infection, recent reports indicate that this is not always the case. To study the possible role of immune responses to hepatitis B core antigen in immunity to HBV infection, chimpanzees were immunized with chimpanzee liver-derived or genetically cloned hepatitis B core antigen and later challenged with known infectious HBV. Two chimpanzees, which received liver-derived or cloned hepatitis B core antigen in Freund's adjuvant and developed hepatitis B core antibody and low-titer hepatitis B e antibody, were completely protected against HBV infection following challenge. In contrast, another chimpanzee, which received liver-derived hepatitis B core antigen without adjuvant, developed hepatitis B core antibody only in serum and had a subclinical HBV infection when challenged. These findings demonstrate that protection against HBV infection can be induced by immunization with hepatitis B core antigen in adjuvant and that protection, in this case, is not solely dependent on hepatitis B surface antibody. This fact has important implications in our understanding of the biology of HBV infection and in the design of future hepatitis B vaccines.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3967809     DOI: 10.1016/0016-5085(85)90148-9

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  25 in total

1.  DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines.

Authors:  H L Davis; M J McCluskie; J L Gerin; R H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

Review 2.  Gene vaccination for hepatitis C.

Authors:  G Inchauspé
Journal:  Springer Semin Immunopathol       Date:  1997

Review 3.  The chimpanzee model for hepatitis B virus infection.

Authors:  Stefan F Wieland
Journal:  Cold Spring Harb Perspect Med       Date:  2015-06-01       Impact factor: 6.915

4.  Induction of protective immunity against rabies by immunization with rabies virus ribonucleoprotein.

Authors:  B Dietzschold; H H Wang; C E Rupprecht; E Celis; M Tollis; H Ertl; E Heber-Katz; H Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

5.  Bicistronic woodchuck hepatitis virus core and gamma interferon DNA vaccine can protect from hepatitis but does not elicit sterilizing antiviral immunity.

Authors:  Jinguo Wang; Shashi A Gujar; Lucyna Cova; Tomasz I Michalak
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

6.  Hybrid hepatitis B virus core-pre-S proteins synthesized in avirulent Salmonella typhimurium and Salmonella typhi for oral vaccination.

Authors:  F Schödel; S M Kelly; D L Peterson; D R Milich; R Curtiss
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

7.  Characterization of cell mediated immune responses to the hepatitis B core protein in man.

Authors:  S P Sylvan; U B Hellström; B Flehmig
Journal:  Clin Exp Immunol       Date:  1987-05       Impact factor: 4.330

8.  Chimeric hepatitis B virus core particles with parts or copies of the hepatitis C virus core protein.

Authors:  A Yoshikawa; T Tanaka; Y Hoshi; N Kato; K Tachibana; H Iizuka; A Machida; H Okamoto; M Yamasaki; Y Miyakawa
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

9.  Murine immune response to HIV-1 p24 core protein following subcutaneous, intraperitoneal and intravenous immunization.

Authors:  L Fyfe; J Maingay; A C Robinson; S E Howie
Journal:  Immunology       Date:  1991-11       Impact factor: 7.397

10.  The position of heterologous epitopes inserted in hepatitis B virus core particles determines their immunogenicity.

Authors:  F Schödel; A M Moriarty; D L Peterson; J A Zheng; J L Hughes; H Will; D J Leturcq; J S McGee; D R Milich
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.